Lesson · 2 min read · Semax
Semax: what the studies show
Semax and modified variants
Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro. N-acetyl Semax and amidated variants change its chemical identity. Evidence for the unmodified peptide does not establish these variants' efficacy or equivalent exposure.
Stroke and imaging findings
A 1997 Russian report compared 30 acute ischemic-stroke patients receiving Semax plus intensive care with 80 receiving conventional treatment. Investigators reported faster improvement in some neurological deficits. The English abstract does not establish randomization or blinding. Concurrent care and unequal groups limit the conclusion.
A 2018 Moscow study gave intranasal Semax or placebo to 24 healthy adults. Brain scans at five and 20 minutes showed a default mode network difference. The controlled human experiment measured an imaging marker. It did not establish better memory or daily function.
Route and clinical benefit
The intranasal imaging experiment provides no repeated-use cognitive protocol. Injectable products require their own evidence. No FDA-approved product was identified. Meaningful clinical benefit for a defined population still requires well-controlled trials.
Quick check
What does the 2018 Semax imaging study support?
Sources
- Gusev et al., 1997: Semax during acute hemispheric ischemic stroke
- Lebedeva et al., September 2018: intranasal Semax and resting-state fMRI
- FDA, July 2026 PCAC: Semax evidence and translation limitations
- HHS: October 2026 peptide compounding policy and identity appendices
- Federal Register, October 30, 2026: draft, nonbinding HHS policy notice
- FDA Drugs@FDA: no application for semax, searched November 6, 2026
Peptiday editorial summary, not clinically reviewed, November 6, 2026. For education only, not medical advice. Talk to a clinician before starting, stopping or changing treatment.